Does bleeding affect patient-reported outcome measures in patients with myelodysplasia or hematologic malignancies: A systematic review

Transfusion

Volumn 54, Issue 4, 2014, Pages 1166-1179

  Estcourt, Lise J ^a,b   Pinchon, Deborah ^c,d   Symington, Emily ^e   Kelly, Anne M ^f   Doree, Carolyn ^a,b   Brunskill, Susan ^a,b   Glidewell, Liz ^g   Stanworth, Simon ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^d KING EDWARD MEMORIAL HOSPITAL   (Australia)

^e CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLEEDING; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; EPISTAXIS; HAIR LOSS; HEMATOLOGIC MALIGNANCY; HEMATURIA; HUMAN; INFECTION; META ANALYSIS; MORTALITY; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; OBSERVATIONAL STUDY; ORAL BLISTER; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; SKIN BRUISING; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VAGINA BLEEDING; WEIGHT REDUCTION;

COHORT STUDIES; CROSS-SECTIONAL STUDIES; HEMATOLOGIC NEOPLASMS; HEMORRHAGE; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELF CONCEPT; SELF REPORT;

EID: 84898911841     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12441     Document Type: Article

References (70)

1. Cella DF,. Quality of life: concepts and definition. J Pain Symptom Manage 1994; 9: 186-192. (Pubitemid 24134451)
2. Estcourt LJ, Birchall J, Lowe D, et al. Platelet transfusions in haematology patients: are we using them appropriately? Vox Sang 2012; 103: 284-293.
3. BCSH. British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122: 10-23.
4. Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012; 380: 1309-1316.
5. Stanworth SJ, Estcourt LJ, Powter G, et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood 2012; 120: Abstract 1.
6. Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013; 121: 537-545.
7. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377: 393-402.
8. Fogarty PF, Tarantino MD, Brainsky A, et al. Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin 2012; 28: 79-87.
9. Butler C, Doree C, Estcourt L, et al. Pathogen-reduced platelets for the prevention of bleeding (protocol). Cochrane Database Syst Rev 2013;(3): CD009072.
10. Estcourt L, Stanworth S, Doree C, et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 2012;(5): CD004269.
11. Heddle NM, Arnold DM, Webert KE,. Time to rethink clinically important outcomes in platelet transfusion trials. Transfusion 2011; 51: 430-434.
12. Webert KE, Arnold DM, Lui Y, et al. A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia. Transfusion 2012; 52: 2466-2474.
13. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997; 337: 1870-1875.
14. Tinmouth A, Tannock IF, Crump M, et al. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion 2004; 44 (12): 1711-1719. (Pubitemid 39644055)
15. Estcourt LJ, Heddle N, Kaufman R, et al. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion 2013; 53: 1531-1543.
16. Centers for Disease Control and Prevention (CDC). Health-Related Quality of Life. [cited 2012 Nov 8]. Available from: http://www.cdc.gov/hrqol/
17. Farnik M, Pierzchala WA,. Instrument development and evaluation for patient-related outcomes assessments. Patient Relat Outcome Meas 2012; 3: 1-7.
18. Rand Health. Medical outcomes study: 36-item short form survey. [cited 2012 Nov 8]. Available from: http://www.rand.org/health/surveys-tools/mos/mos- core-36item.html
19. Functional Assessment of Chronic Illness Therapy (FACIT). Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT). 2007 [cited 2012 Nov 8]. Available from: http://www.facit.org/FACITOrg/Questionnaires
20. Leventhal H,. Findings and theory in the study of fear communications. Adv Exp Soc Psychol 1970; 5: 119-186.
21. Leventhal H, Meyer D, Nerenz DR,. The common sense representation of illness danger. In:, Rachman S, editor. Medical psychology. Vol. II. Oxford, UK: Pergamon Press; 1980. p. 7-30.
22. Leventhal H, Diefenbach MA, Leventhal EA,. Illness cognition: using common sense to understand treatment adeherence and affect cognition interactions. Cognit Ther Res 1992; 16: 143-163.
23. Hagger MS, Orbell S,. A meta-analytic review of the common-sense model of illness representations. Psychol Health 2003; 18: 141-184. (Pubitemid 36364010)
24. Lau RR, Hartman KA,. Common sense representations of common illnesses. Health Psychol 1983; 5: 119-186.
25. Weinman J, Petrie KJ, Moss-Morris R, et al. The Illness Perception Questionnaire: a new method for assessing the cognitive representation of illness. Psychol Health 1996; 11: 431-445.
26. Moss-Morris R, Weinman J, Petrie KJ, et al. The revised illness perception questionnaire (IPQ-R). Psychol Health 2002; 17: 1-16.
27. Mc Sharry J, Moss-Morris R, Kendrick T,. Illness perceptions and glycaemic control in diabetes: a systematic review with meta-analysis. Diabet Med 2011; 28: 1300-1310.
28. Higgins JP, Deeks JJ,. Selecting studies and collecting data. In:, Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration, 2011. [cited 2013 Sep 13]. Available from: www.cochrane-handbook.org
29. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
30. Sterne J, Egger M, Moher D,. Addressing reporting biases. In:, Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration, 2011. [cited 2013 Sep 13]. Available from: www.cochrane-handbook.org
31. Sanderson S, Tatt ID, Higgins JP,. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007; 36: 666-676. (Pubitemid 47244573)
32. Katrak P, Bialocerkowski AE, Massy-Westropp N, et al. A systematic review of the content of critical appraisal tools. BMC Med Res Methodol 2004; 4: 22.
33. Crowe M, Sheppard L,. A review of critical appraisal tools show they lack rigor: alternative tool structure is proposed. J Clin Epidemiol 2011; 64: 79-89.
34. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007; 4: e296.
35. Eysenbech G,. Improving the quality of web surveys: the checklist for reporting results of internet e-surveys (CHERRIES). J Med Internet Res 2004; 6: e34.
36. Tong A, Sainsbury P, Craig J,. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 2007; 19: 349-357. (Pubitemid 350186969)
37. List AF, Mathias S, Crosby RD, et al. Disease burden and treatment impact associated with myelodysplastic syndromes: preliminary findings from a web-based survey. ASH Annu Meet Abstr 2009; 114: 4522.
38. Anderson KO, Giralt SA, Mendoza TR, et al. Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant 2007; 39: 759-766. (Pubitemid 46901974)
39. Ruland C, Holte H, Roislien J, et al. Effects of a computer-supported interactive tailored patient assessment tool on patient care, symptom distress, and patients' need for symptom management support: a randomized clinical trial. J Am Med Inform Assoc 2010; 17: 403-410.
40. McKenna SP, Twiss J, Wilburn JN, et al. Investigation of the impact of myelodysplasia (MDS) from the patients' perspective. ASH Annu Meet Abstr 2011; 118: 5049.
41. Feyer P, Kleeberg UR, Steingraber M, et al. Frequency of side effects in outpatient cancer care and their influence on patient satisfaction-a prospective survey using the PASQOC questionnaire. Support Care Cancer 2008; 16: 567-575.
42. Arnold B, Dhar J, Parks-Vernizzi E, et al. Translation and linguistic validation of the FACT-Th18 for use with cancer patients with thrombocytopenia worldwide. Value Health 2012; 15: A236.
43. ClinicalTrials.gov. NCT01615146. Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: the OPTIMAL Pilot. 2012. [cited 2013 Jan 7]. Available from: http://clinicaltrials.gov/show/NCT01615146
44. Persson L, Hallberg IR, Ohlsson O,. Acute leukaemia and malignant lymphoma patients' experiences of disease, treatment and nursing care during the active treatment phase: an explorative study. Eur J Cancer Care (Engl) 1995; 4: 133-142.
45. On behalf of the MDS Foundation and its Board of Directors. P097 Disease burden and treatment impact associated with myelodysplastic syndromes: initial estimates. Leuk Res 2009; 33 (Suppl 1): S115-116.
46. Crosby RD, Kolotkin RL, Williams GR,. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003; 56: 395-407. (Pubitemid 36694091)
47. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47: 81-87. (Pubitemid 24034293)
48. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362: 600-613.
49. Pendry K, Davies T,. An audit of the use and wastage in the North West of England and North Wales-where have all the platelets gone? Blood Transfus Matters 2011; 34: 17-19.
50. Huwiler-Muntener K, Juni P, Junker C, et al. Quality of reporting of randomized trials as a measure of methodologic quality. J Am Med Assoc 2002; 287: 2801-2804. (Pubitemid 34591968)
51. Juni P, Witschi A, Bloch R, et al. The hazards of scoring the quality of clinical trials for meta-analysis. J Am Med Assoc 1999; 282: 1054-1060. (Pubitemid 29436453)
52. Greenland S, O'Rourke K,. On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions. Biostatistics 2001; 2: 463-471.
53. The EuroQoL Group. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16: 199-208.
54. Brooks R,. EuroQol: the current state of play. Health Policy 1996; 37: 53-72. (Pubitemid 26191458)
55. Jakobsson U, Hallberg IR, Westergren A,. Exploring determinants for quality of life among older people in pain and in need of help for daily living. J Clin Nurs 2007; 16 (3A): 95-104.
56. Lorr M, McNair DM, Heuchert JW, et al. POMS Profile of Mood States. 2004.
57. Bowling A,. Measuring disease. 2nd ed. Oxford, UK: Oxford University Press; 2001.
58. Nyenhuis DL, Yamamoto C, Luchetta T, et al. Adult and geriatric normative data and validation of the profile of mood states. J Clin Psychol 1999; 55: 79-86. (Pubitemid 29044742)
59. Hays RD, Sherbourne CD, Mazel RM,. User's manual for the medical outcomes study (MOS) core: measures of health-related quality of life. Santa Monica (CA): RAND Corporation; 1994.
60. Eriksson M, Lindstrom B,. Validity of Antonovsky's sense of coherence scale: a systematic review. J Epidemiol Community Health 2005; 59: 460-466. (Pubitemid 40791030)
61. Bowling A,. Measuring health. 2nd ed. Oxford, UK: Oxford University Press; 1997.
62. Persson L, Hallberg IR, Ohlsson O,. Survivors of acute leukaemia and highly malignant lymphoma-retrospective views of daily life problems during treatment and when in remission. J Adv Nurs 1997; 25: 68-78. (Pubitemid 127454772)
63. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376. (Pubitemid 23073154)
64. Hjermstad MJ, Fayers PM, Bjordal K, et al. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ = C30 (+3). J Clin Oncol 1998; 16: 1188-1196. (Pubitemid 28108757)
65. Osoba D, Aaronson N, Zee B, et al. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Qual Life Res 1997; 6: 103-108.
66. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579. (Pubitemid 23071057)
67. Webster K, Cella D, Yost K,. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003; 1: 79.
68. Cella D, Beaumont J, Webster K, et al. Measuring the concerns of cancer patients with low platelet counts: the Functional Assessment of Cancer Therapy-Thrombocytopenia (FACT-Th) questionnaire. Support Care Cancer 2006; 14: 1220-1231. (Pubitemid 44800641)
69. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000; 89: 1634-1646.
70. Cleeland CS,. The M.D. Anderson Symptom Inventory User Guide [Draft]. 2010. [cited 2013 Sep 9]. Available from: http://www.mdanderson.org/education- and-research/departments-programs-and-labs/departments-and-divisions/ sympton-research/sympton-assessment-tools/MDASI-userguide.pdf